Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans

Bid Saw UK Pharma Major’s Shares Rise

GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.

GSK Skyline
GSK will now press ahead with its spin-out plan, unless another buyer emerges with a higher bid. • Source: Alamy

Unilever has abandoned its buyout bid for GlaxoSmithKline’s consumer health division after the UK pharma company rejected a £50bn ($67.8bn) offer.

That means GSK looks set to proceed with the spin-out and stock market flotation of the division this summer as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip